NCT06697301 2025-11-12Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.Eikon TherapeuticsPhase 2/3 Recruiting740 enrolled